<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753440</url>
  </required_header>
  <id_info>
    <org_study_id>AHEPA_CTL_01</org_study_id>
    <nct_id>NCT01753440</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cells Implantation Combined With Coronary Bypass Grafting in Patients With Ischemic Cardiomyopathy</brief_title>
  <official_title>Study on the Safety and Efficacy of Allogeneic Mesenchymal Stem Cell Implantation Combined With Bypass Grafting in Patients With Coronary Artery Disease and Ischemic Cardiomyopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate safety and efficacy of intramyocardial
      implantation of a novel mesenchymal precursor cell type (iMP) in patients with ischemic
      cardiomyopathy at the time of coronary artery bypass grafting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to investigates in situ cardiac regeneration utilizing precision delivery of
      a novel mesenchymal precursor cell type (iMP) during coronary artery bypass surgery (CABG) in
      patients with ischemic cardiomyopathy (LVEF &lt; 40 %). Preoperative scintigraphy imaging
      (SPECT) will be used to identify hibernating myocardium not suitable for conventional
      myocardial revascularization for iMP implantation. iMP cells will be implanted
      intramyocardially in predefined viable peri-infarct areas that show poor perfusion, which
      could not be grafted due to poor target vessel quality. Postoperatively, SPECT will be used
      to identify changes in scar area.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iMP-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Major adverse cardiac and cerebrovascular events including death, postoperative myocardial infarction, need for revascularization, stroke, hospitalization for worsening heart failure, myocardial rupture, infectious myocarditis, or sustained ventricular arrhythmias.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypersensitivity</measure>
    <time_frame>12 months</time_frame>
    <description>Hypersensitivity reaction (fever, urticaria, hemolytic anemia, hypotension, immune thrombocytopenia)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scar reduction</measure>
    <time_frame>4 months</time_frame>
    <description>Myocardial scar size reduction assessed with SPECT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar reduction</measure>
    <time_frame>12 months</time_frame>
    <description>Myocardial scar size reduction assess with SPECT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF</measure>
    <time_frame>12 months</time_frame>
    <description>Left ventricular ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life evaluated with MLHFQ</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Stem cells implantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with severe coronary artery disease and chronic ischemic cardiomyopathy with a LVEF ≤40% who are scheduled for elective CABG according to accepted guidelines. Additional criteria include the following: age &lt;75 years, history of myocardial infarction (not less than 14 days before the procedure), LVEF ≤40 % assessed with echocardiography, and a distinct area of dyskinetic or akinetic left ventricular myocardium corresponding with the infarct localization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).</intervention_name>
    <description>Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).</description>
    <arm_group_label>Stem cells implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 75 years

          -  Severe coronary artery disease amenable to surgical revascularization according to
             current guidelines

          -  History of acute myocardial infarction at least 14 days previously

          -  Left ventricular ejection fraction (LVEF) ≤ 40% as assessed with echocardiography

          -  Distinct area of dyskinetic or akinetic left ventricular myocardium corresponding with
             the infarct localization

          -  Patient's informed consent obtained

        Exclusion Criteria:

          -  Emergency operation

          -  Debilitating chronic disease (eg. malignancy or terminal renal failure)

          -  Concomitant valve surgery

          -  Previous cardiac surgery

          -  Malignant ventricular arrhythmias

          -  Haematologic disease

          -  Woman in reproductive age

          -  Severe psychiatric illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakos Anastasiadis, MD, PhD FETCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHEPA University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012 Dec 12;308(22):2369-79. Erratum in: JAMA. 2013 Aug 21;310(7):750. George, Richard [added]; Lardo, Albert [added].</citation>
    <PMID>23117550</PMID>
  </reference>
  <reference>
    <citation>Anastasiadis K, Antonitsis P, Doumas A, Koliakos G, Argiriadou H, Vaitsopoulou C, Tossios P, Papakonstantinou C, Westaby S. Stem cells transplantation combined with long-term mechanical circulatory support enhances myocardial viability in end-stage ischemic cardiomyopathy. Int J Cardiol. 2012 Mar 22;155(3):e51-3. doi: 10.1016/j.ijcard.2011.07.062. Epub 2011 Aug 17.</citation>
    <PMID>21852003</PMID>
  </reference>
  <reference>
    <citation>Menasche P. Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol. 2011 Feb;50(2):258-65. doi: 10.1016/j.yjmcc.2010.06.010. Epub 2010 Jun 30. Review.</citation>
    <PMID>20600097</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>Kyriakos Anastasiadis</investigator_full_name>
    <investigator_title>Professor Kyriakos Anastasiadis</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>heart failure</keyword>
  <keyword>stem cells implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

